4.7 Article

Defining the structure-activity relationship for a novel class of allosteric MKP5 inhibitors

期刊

出版社

ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.ejmech.2022.114712

关键词

-

资金

  1. NIH [R01AR66003, R35GM122473, T32 AI055403, R35-DM122473]
  2. Blavatnik Innovations Award
  3. Program in Innovative Therapeutics for Connecticuts Health
  4. National Institute of General Medical Sciences from the National Institutes of Health [P30 GM124165]
  5. DOE Office of Science [DE-AC02-06CH11357, DE-AC02-98CH10886]

向作者/读者索取更多资源

This study explores the structure-activity relationship of a class of MKP5 inhibitors and designs and synthesizes a series of derivative compounds for evaluation of MKP5 inhibition. The crystal structures of enzyme-inhibitor complexes are further analyzed to elucidate the necessary requirements for MKP5 inhibition. The results lay the foundation for the development of more potent MKP5 allosteric inhibitors for the treatment of dystrophic muscle disease.
Mitogen-activated protein kinase (MAPK) phosphatase 5 (MKP5) is responsible for regulating the activity of the stress-responsive MAPKs and has been put forth as a potential therapeutic target for a number of diseases, including dystrophic muscle disease a fatal rare disease which has neither a treatment nor cure. In previous work, we identified Compound 1 (3,3-dimethyl-1-((9-(methylthio)-5,6-dihydrothieno[3,4-h]quinazolin-2-yl)thio)butan-2-one) as the lead compound of a novel class of MKP5 inhibitors. In this work, we explore the structure-activity relationship for inhibition of MKP5 through modifications to the scaffold and functional groups present in 1. A series of derivative compounds was designed, synthesized, and evaluated for inhibition of MKP5. In addition, the X-ray crystal structures of six enzyme-inhibitor complexes were solved, further elucidating the necessary requirements for MKP5 inhibition. We found that the parallel-displaced 7C-7C interaction between the inhibitor three-ring core and Tyr435 is critical for modulating potency, and that modifications to the core and functionalization at the C-9 position are essential for ensuring proper positioning of the core for this interaction. These results lay the foundation from which more potent MKP5 allosteric inhibitors can be developed for potential therapeutics towards the treatment of dystrophic muscle disease.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据